文献速递糖尿病

吡格列酮暴露降低胰岛素治疗2型糖尿病患者的全因死亡风险

Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

结果显示,吡格列酮使用者的全因死亡风险显著降低(aHR 0.47,95%CI 0.38-0.58,P<0.001),非心血管死亡风险亦降低(aHR 0.50,95%CI 0.38-0.66),但心血管死亡及主要心血管事件风险无显著差异。

要点

  • 吡格列酮使用与胰岛素治疗T2DM患者全因死亡风险降低相关(aHR 0.47)。
  • 非心血管死亡风险显著降低(aHR 0.50),心血管死亡风险无显著差异。
  • 因心血管疾病住院、卒中住院及新发心力衰竭风险无显著差异。

核心结论

  • 吡格列酮使用可降低接受胰岛素治疗的2型糖尿病患者的全因死亡和非心血管死亡风险。

研究设计与样本

  • 比较2579例吡格列酮使用者与2579例匹配非使用者的全因死亡和心血管事件发生率。

主要发现

  • 吡格列酮使用者与非使用者的死亡率分别为15.02和30.26每1000人年。
  • 调整后全因死亡风险比(aHR)为0.47(95%CI 0.38-0.58,P<0.001)。
  • 心血管死亡aHR为0.78(95%CI 0.51-1.19),非心血管死亡aHR为0.50(95%CI 0.38-0.66)。
  • 因冠心病住院、卒中住院及新发心力衰竭的aHR在两组间无显著差异。

临床怎么用

  • 对于接受胰岛素治疗的2型糖尿病患者,吡格列酮使用可能与全因死亡风险降低相关,但需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The long-term safety and benefit of pioglitazone use in combination with insulin are still uncertain. OBJECTIVE: This study compared the risks of all-cause mortality and major cardiovascular (CV) events between pioglitazone users and nonusers receiving insulin therapy. DESIGN, SETTING AND PATIENTS: We conducted a 13-year retrospective cohort study by using data from the population-based National Health Insurance Research Database in Taiwan. A total of 20 376 patients with type 2 diabetes mellitus (T2DM) receiving insulin therapy were enrolled during 2000 to 2012. Overall, the incidence rates of all-cause mortality and CV events were compared between 2579 pioglitazone users and 2579 matched nonusers. RESULTS: After adjustment for age, sex, comorbidities, Diabetes Complications Severity Index scores, and drugs used, mortality rates were 30.26 and 15.02 per 1000 person-years for pioglitazone nonusers and users, respectively. The adjusted hazard ratio (aHR) of mortality was 0.47 (95% confidence interval [CI]: 0.38-0.58, P < 0.001) for pioglitazone users compared with nonusers. The aHRs of CV and non-CV deaths were 0.78 (95% CI: 0.51-1.19) and 0.50 (95% CI: 0.38-0.66), respectively. The aHRs of hospitalized coronary artery disease, hospitalized stroke, and incident heart failure were not significantly different between pioglitazone users and nonusers. CONCLUSIONS: This nationwide cohort study demonstrated that pioglitazone use reduced the risks of all-cause mortality and non-CV death for patients with T2DM undergoing insulin therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yen FS, Wang HC, Pan CW, et al. Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2020. PMID: 31544207. doi:10.1210/clinem/dgz026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。